US FDA approves first rapid diagnostic test for Ebola: October’s industry headlines
Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and…
Browsing: Drug Development
A peek behind the paper – Shujuan Sun on using existing antibiotics as antifungals
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals’ as we ask the authors about Candida infections, the potential repurposing of antibiotics and the future of this field.
US FDA warns of serious liver injury linked to hepatitis C drugs: September’s industry headlines
Take a look at this month’s industry headlines including FDA warnings over hepatitis C drugs in patients with liver injury, a new infectious diseases strategy for the UK and priority review for Merck’s Ebola vaccine.
Identifying novel antifungal proteins from ‘killer yeasts’ – an interview with Paul Rowley
In this interview, Paul Rowley (University of Idaho, ID, USA) speaks about his research identifying novel antifungal proteins from Saccharomyces cerevisiae yeasts and whether these could be translated into the medications of the future.
Combating resistance while maintaining innovation: The future of antimicrobial stewardship
In this perspective piece for Future Microbiology the authors argue that there is a lack of innovation to meet the current shortcomings of antibiotic R&D.
A peek behind the paper – Sidharth Chopra on drug repurposing to tackle antimicrobial resistance
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘An update on drug repurposing: Is it useful for tacking antimicrobial resistance?’ as we ask the authors about what challenges and limitations drug repurposing faces, in addition to why this strategy could be a promising alternative to the traditional drug discovery pipeline.
First new oral and IV antibiotic with novel mechanism of action approved in nearly two decades
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
US FDA approves Pretomanid tablets for drug-resistant tuberculosis
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
Two Ebola treatments prove effective in DRC outbreak
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
Coagulation factors show activity against drug-resistant Gram-negative bacteria
Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.
